Sandhoff disease is a severe inherited neurodegenerative disorder resulting from deficiency of the beta-subunit of hexosaminidases A and B, lysosomal hydrolases involved in the degradation of G(M2) ganglioside and related metabolites. Currently, there is no viable treatment for the disease. Here, we show that adenovirus-mediated transfer of the beta-subunit of beta-hexosaminidase restored Hex A and Hex B activity after infection of Sandhoff fibroblasts. Gene transfer following intracerebral injection in a murine model of Sandhoff disease resulted in near-normal level of enzymatic activity in the entire brain at the different doses tested. The addition of hyperosmotic concentrations of mannitol to the adenoviral vector resulted in an enhancement of vector diffusion in the injected hemisphere. Adenoviral-induced lesions were found in brains injected with a high dose of the vector, but were not detected in brains injected with 100-fold lower doses, even in the presence of mannitol. Our data underline the advantage of the adjunction of mannitol to low doses of the adenoviral vector, allowing a high and diffuse transduction efficiency without viral cytotoxicity.
Widespread distribution of beta-hexosaminidase activity in the brain of a Sandhoff mouse model after coinjection of adenoviral vector and mannitol
Bourgoin, C.; Emiliani, C.; Kremer, E. J.; Gelot, A.; Tancini, B.; Gravel, R. A.; Drugan, C.; Orlacchio, A.; Poenaru, L.; Caillaud, C.
2003-10 / vol 10 / pages 1841-1849
IGMM team(s) involved in this publication
Eric J Kremer
Adenovirus: receptors, trafficking, immunogenicity & vectorology
delivery; mediated gene-transfer; central-nervous-system; transgene expression; efficient; adenoviral vector; barrier; beta-hexosaminidase; central nervous system; diseases; human tay-sachs; integration; mannitol; mouse model; sandhoff disease; vii mice